July 24, 2014: Gilead's earnings report will be closely watched on both Wall Street and Capitol Hill, where the argument about how much the world’s second-most-valuable biotech company should charge for its new $84,000 hepatitis C drug Sovaldi is getting more and more heated.
July 24, 2014: Brand-name drug makers are being accused of hiding behind a mandated safety program (Risk Evaluation and Mitigation Strategies) to thwart aspiring generic rivals.
July 24, 2014: The director of a U.S. government bioterror lab that potentially exposed scores of workers to live anthrax last month has resigned, the U.S. Centers for Disease Control and Prevention.
July 24, 2014: Paracetamol is no better than placebo at speeding recovery from acute episodes of lower back pain or improving pain levels, function, sleep, or quality of life, according to the first large randomised trial to compare the effectiveness of paracetamol with placebo for low-back pain.
